David Resnick - patent attorney, partner, and biotechnology practice co-leader at Nixon Peabody - will be joining us to discuss intellectual property strategies for life science startups. We will talk about constructing a robust life science IP portfolio, as well as strategies used by startups to build a moat around your business and technology in order to maximize your competitive advantage. Topics will include provisional vs. non-provisional patents, PCT filings, deciding when to use patents vs. trade secrets, establishing freedom to operate, managing IP, leveraging licensing opportunities, and strategies for filing patents.

Speaker: David Resnick, Patent Attorney, Partner, Biotech Lead @ Nixon Peabody

About the Speaker:

David Resnick is a partner in the Intellectual Property practice at Nixon Peabody and the leader of the Patent Team. He works with both startup and established life sciences companies, as well as major U.S. research institutions, to develop comprehensive patent strategies to protect their IP. His practice focuses on strategic portfolio management, patent prosecution, freedom-to-operate, and associated client counseling. David has extensive experience with microbiome-related technologies, pharmacogenomics, proteomics, tissue engineering, gene therapy, and regenerative medicine.

David Resnick, patent attorney, partner, and biotechnology practice co-leader at Nixon Peabody, will be joining us to discuss intellectual property strategies for life science startups. We will talk about constructing a robust life science IP portfolio, as well as strategies used by startups to build a moat around your business & technology in order to maximize your competitive advantage. Topics will include provisional vs non-provisional patents, PCT filings, deciding when to use patents vs trade secrets, establishing freedom to operate, managing IP, leveraging licensing opportunities, and strategies for filing patents.

Strategies to Build a Robust Life Science IP Portfolio